Abstract
Lung cancer is the leading cause of cancer related death in Poland. About 85% of all lung cancer constitutes non-small cancer (NSCLC), in which the role of cytotoxic and molecularly targeted drugs is increasing. This article presents the current evidence- based recommendations for the use of these methods in clinical practice in NSCLC and malignant pleural mesothelioma.
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / surgery
-
Evidence-Based Medicine
-
Humans
-
Immunotherapy / methods
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / surgery
-
Mesothelioma / diagnosis
-
Mesothelioma / drug therapy*
-
Mesothelioma / surgery
-
Mesothelioma, Malignant
-
Molecular Targeted Therapy*
-
Pleural Neoplasms / diagnosis
-
Pleural Neoplasms / drug therapy*
-
Pleural Neoplasms / surgery
-
Poland
-
Postoperative Care
-
Practice Guidelines as Topic*
-
Premedication
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases